OBJECTIVE: To investigate the association between maternal oxidative stress at mid-gestation and subsequent development of pregnancy complications. STUDY DESIGN: A total of 503 healthy pregnant women provided their blood and urine samples at 24 to 26 weeks of gestation and were prospectively followed through postpartum. These samples were used to assess a variety of oxidative stress markers, including plasma total antioxidant capacity, 8-isoprostane, erythrocyte glutathione peroxidase and superoxide dismutase activity, and urinary 8-hydroxydeoxyguanosine (8-OHdG). RESULTS: Compared with women with uncomplicated pregnancies, significantly higher plasma 8-isoprostane levels were noted in women who developed preeclampsia (P = .008) and small-for-gestational age infants (P = .002), while higher urinary 8-OHdG concentrations were noted in women who subsequently had low-birth-weight neonates (<2500 g, P = .043). CONCLUSION: Increased maternal oxidative stress at mid-gestation was associated with subsequent pregnancy complications.
OBJECTIVE: To investigate the association between maternal oxidative stress at mid-gestation and subsequent development of pregnancy complications. STUDY DESIGN: A total of 503 healthy pregnant women provided their blood and urine samples at 24 to 26 weeks of gestation and were prospectively followed through postpartum. These samples were used to assess a variety of oxidative stress markers, including plasma total antioxidant capacity, 8-isoprostane, erythrocyte glutathione peroxidase and superoxide dismutase activity, and urinary 8-hydroxydeoxyguanosine (8-OHdG). RESULTS: Compared with women with uncomplicated pregnancies, significantly higher plasma 8-isoprostane levels were noted in women who developed preeclampsia (P = .008) and small-for-gestational age infants (P = .002), while higher urinary 8-OHdG concentrations were noted in women who subsequently had low-birth-weight neonates (<2500 g, P = .043). CONCLUSION: Increased maternal oxidative stress at mid-gestation was associated with subsequent pregnancy complications.
Authors: Muraly Puttabyatappa; Margaret Banker; Lixia Zeng; Jaclyn M Goodrich; Steven E Domino; Dana C Dolinoy; John D Meeker; Subramaniam Pennathur; Peter X K Song; Vasantha Padmanabhan Journal: J Clin Endocrinol Metab Date: 2020-02-01 Impact factor: 5.958
Authors: Kelly K Ferguson; John D Meeker; Thomas F McElrath; Bhramar Mukherjee; David E Cantonwine Journal: Am J Obstet Gynecol Date: 2016-12-30 Impact factor: 8.661
Authors: Stephanie M Eick; Kelly K Ferguson; Ginger L Milne; Rafael Rios-McConnell; Carmen Vélez-Vega; Zaira Rosario; Akram Alshawabkeh; José F Cordero; John D Meeker Journal: Free Radic Biol Med Date: 2019-11-05 Impact factor: 7.376
Authors: Scott W Walsh; Anuja A Chumble; Sonya L Washington; Kellie J Archer; Sinem E Sahingur; Jerome F Strauss Journal: J Reprod Immunol Date: 2017-06-03 Impact factor: 4.054
Authors: Kelly K Ferguson; Thomas F McElrath; Yin-Hsiu Chen; Rita Loch-Caruso; Bhramar Mukherjee; John D Meeker Journal: Am J Obstet Gynecol Date: 2014-08-08 Impact factor: 8.661
Authors: Kelly K Ferguson; Elizabeth M Kamai; David E Cantonwine; Bhramar Mukherjee; John D Meeker; Thomas F McElrath Journal: Am J Reprod Immunol Date: 2018-07-08 Impact factor: 3.886
Authors: Emma M Rosen; Thomas J van 't Erve; Jonathan Boss; Sheela Sathyanarayana; Emily S Barrett; Ruby H N Nguyen; Nicole R Bush; Ginger L Milne; Thomas F McElrath; Shanna H Swan; Kelly K Ferguson Journal: Free Radic Biol Med Date: 2018-11-14 Impact factor: 7.376